Tirdzniecība Ocugen, Inc. - OCGN CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Starpība | 0.05 | ||||||||
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025457% | ||||||||
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.003235% | ||||||||
Nakts laika nodeva | 21:00 (UTC) | ||||||||
Min. tirgotais daudzums | 1 | ||||||||
Valūta | USD | ||||||||
Drošības rezerve | 20% | ||||||||
Fondu birža | United States of America | ||||||||
Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Ocugen Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Iepriekš. aizvērt* | 0.43 |
Atvērt* | 0.43 |
Izmaiņas par 1 gadu* | -81.47% |
Dienas Diapazons* | 0.43 - 0.43 |
52 ned Diapazons | 0.44-3.11 |
Vidējais apjoms (10 dienas) | 12.86M |
Vidējais apjoms (3 mēneši) | 155.86M |
Tirgus Kapitalizācija | 120.03M |
Cenas/Peļņas Attiecība | -100.00K |
Izvietotās Akcijas | 260.93M |
Ieņēmumi | N/A |
EPS | -0.36 |
Dividende (Ienesīgums %) | N/A |
Beta | 3.89 |
Nākamās Peļņas Datums | Aug 3, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
---|---|---|---|---|---|---|
Jun 1, 2023 | 0.43 | 0.00 | 0.00% | 0.43 | 0.43 | 0.43 |
May 31, 2023 | 0.43 | 0.00 | 0.00% | 0.43 | 0.44 | 0.43 |
May 30, 2023 | 0.43 | -0.02 | -4.44% | 0.45 | 0.45 | 0.43 |
May 26, 2023 | 0.44 | 0.01 | 2.33% | 0.43 | 0.44 | 0.42 |
May 25, 2023 | 0.43 | -0.04 | -8.51% | 0.47 | 0.47 | 0.43 |
May 24, 2023 | 0.45 | -0.08 | -15.09% | 0.53 | 0.53 | 0.43 |
May 23, 2023 | 0.69 | -0.01 | -1.43% | 0.70 | 0.75 | 0.69 |
May 22, 2023 | 0.69 | 0.05 | 7.81% | 0.64 | 0.71 | 0.63 |
May 19, 2023 | 0.65 | 0.01 | 1.56% | 0.64 | 0.65 | 0.63 |
May 18, 2023 | 0.63 | -0.04 | -5.97% | 0.67 | 0.67 | 0.61 |
May 17, 2023 | 0.67 | 0.00 | 0.00% | 0.67 | 0.67 | 0.65 |
May 16, 2023 | 0.67 | -0.01 | -1.47% | 0.68 | 0.71 | 0.66 |
May 15, 2023 | 0.71 | 0.06 | 9.23% | 0.65 | 0.72 | 0.65 |
May 12, 2023 | 0.65 | -0.04 | -5.80% | 0.69 | 0.69 | 0.64 |
May 11, 2023 | 0.68 | -0.05 | -6.85% | 0.73 | 0.73 | 0.67 |
May 10, 2023 | 0.72 | 0.01 | 1.41% | 0.71 | 0.74 | 0.70 |
May 9, 2023 | 0.70 | 0.00 | 0.00% | 0.70 | 0.71 | 0.67 |
May 8, 2023 | 0.70 | 0.00 | 0.00% | 0.70 | 0.72 | 0.68 |
May 5, 2023 | 0.67 | -0.02 | -2.90% | 0.69 | 0.69 | 0.66 |
May 4, 2023 | 0.67 | -0.01 | -1.47% | 0.68 | 0.69 | 0.65 |
Ocugen, Inc. Events
Laiks (UTC) (UTC) | Valsts | Notikums |
---|---|---|
Monday, June 5, 2023 | ||
Laiks (UTC) (UTC) 20:30 | Valsts US
| Notikums Ocugen Inc at Biotechnology Industry Organization (BIO) International Convention Ocugen Inc at Biotechnology Industry Organization (BIO) International ConventionForecast -Previous - |
Wednesday, June 7, 2023 | ||
Laiks (UTC) (UTC) 12:00 | Valsts US
| Notikums Ocugen Inc Annual Shareholders Meeting Ocugen Inc Annual Shareholders MeetingForecast -Previous - |
Friday, June 9, 2023 | ||
Laiks (UTC) (UTC) 12:00 | Valsts US
| Notikums Ocugen Inc Annual Shareholders Meeting Ocugen Inc Annual Shareholders MeetingForecast -Previous - |
Thursday, August 3, 2023 | ||
Laiks (UTC) (UTC) 12:30 | Valsts US
| Notikums Q2 2023 Ocugen Inc Earnings Release Q2 2023 Ocugen Inc Earnings ReleaseForecast -Previous - |
Monday, November 6, 2023 | ||
Laiks (UTC) (UTC) 13:30 | Valsts US
| Notikums Q3 2023 Ocugen Inc Earnings Release Q3 2023 Ocugen Inc Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kopējie ienākumi | 0 | 0 | 0.04262 | 0 | 0 |
Ienākumi | 0 | 0.04262 | 0 | ||
Kopējie Darbības Izdevumi | 84.868 | 57.628 | 21.3273 | 14.5038 | 28.568 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 35.111 | 22.92 | 7.97405 | 6.0771 | 10.204 |
Pētniecība un Attīstība | 49.757 | 35.108 | 13.3533 | 8.08552 | 15.634 |
Neparedzēti Izdevumi (Ienākumi) | -0.4 | 0 | 0.34114 | 2.73 | |
Darbības Izdevumi | -84.868 | -57.628 | -21.2847 | -14.5038 | -28.568 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.079 | -0.71989 | -4.95401 | 20.031 | |
Citi, Neto | 3.517 | -0.71 | 0.18266 | -0.78487 | -0.106 |
Neto Ienākumi Pirms Nodokļu Nomaksas | -81.351 | -58.417 | -21.822 | -20.2426 | -8.643 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
Neto Ienākumi | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
Total Adjustments to Net Income | 0 | -12.5463 | 0.121 | ||
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -81.351 | -58.365 | -34.3683 | -20.2426 | -8.522 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -81.351 | -58.365 | -34.3683 | -20.2426 | -8.522 |
Atšķaidītie Neto Ienākumi | -81.351 | -58.365 | -34.3683 | -20.2426 | -8.522 |
Atšķaidītie Ienākumi par Akcijām | 214.6 | 195.013 | 112.236 | 13.8938 | 0.60676 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.37908 | -0.29929 | -0.30621 | -1.45695 | -14.045 |
Dividends per Share - Common Stock Primary Issue | |||||
Atšķaidītā Normalizētā Peļņa par Akciju | -0.37908 | -0.30062 | -0.30621 | -1.4324 | -9.54575 |
Ārkārtas Posteņi Kopā | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kopējie ienākumi | 0 | 0 | 0 | 0 | 0 |
Kopējie Darbības Izdevumi | 17.751 | 24.15 | 23.119 | 19.565 | 18.034 |
Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 8.193 | 6.937 | 7.497 | 10.558 | 10.119 |
Pētniecība un Attīstība | 9.558 | 17.213 | 15.622 | 9.007 | 7.915 |
Darbības Izdevumi | -17.751 | -24.15 | -23.119 | -19.565 | -18.034 |
Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | |||||
Neto Ienākumi Pirms Nodokļu Nomaksas | -16.498 | -21.939 | -21.922 | -19.471 | -18.019 |
Neto Ienākumi Pēc Nodokļu Nomaksas | -16.498 | -21.939 | -21.922 | -19.471 | -18.019 |
Neto Ienākumi Pirms Ārkārtas Posteņiem | -16.498 | -21.939 | -21.922 | -19.471 | -18.019 |
Neto Ienākumi | -16.498 | -21.939 | -21.922 | -19.471 | -18.019 |
Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -16.499 | -21.939 | -21.922 | -19.471 | -18.019 |
Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -16.499 | -21.939 | -21.922 | -19.471 | -18.019 |
Atšķaidītie Neto Ienākumi | -16.499 | -21.939 | -21.922 | -19.471 | -18.019 |
Atšķaidītie Ienākumi par Akcijām | 225.524 | 220.133 | 216.591 | 215.863 | 205.693 |
Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.07316 | -0.09966 | -0.10121 | -0.0902 | -0.0876 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Atšķaidītā Normalizētā Peļņa par Akciju | -0.07316 | -0.09966 | -0.10121 | -0.0902 | -0.0876 |
Ienākumi | |||||
Citi, Neto | 1.253 | 2.211 | 1.197 | 0.094 | 0.015 |
Total Adjustments to Net Income | -0.001 | ||||
Neparedzēti Izdevumi (Ienākumi) |
- Ikgadējs
- Ceturkšņa
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 98.492 | 102.646 | 25.8777 | 15.7662 | 16.4 |
Nauda un Īstermiņa Ieguldījumi | 90.934 | 94.958 | 24.0393 | 7.44405 | 15.542 |
Nauda un Ekvivalenti | 77.563 | 94.958 | 24.0393 | 7.44405 | 15.542 |
Prepaid Expenses | 7.558 | 2.7 | 1.83836 | 1.32217 | 0.686 |
Total Assets | 108.632 | 105.761 | 27.3764 | 16.8074 | 17.428 |
Property/Plant/Equipment, Total - Net | 9.963 | 2.751 | 1.06662 | 0.22246 | 0.141 |
Intangibles, Net | |||||
Other Long Term Assets, Total | 0.177 | 0.364 | 0.43205 | 0.81876 | 0.887 |
Total Current Liabilities | 18.46 | 7 | 3.61355 | 4.54396 | 2.873 |
Accounts Payable | 8.062 | 2.312 | 0.39503 | 1.89561 | 1.59 |
Accrued Expenses | 10.398 | 4.688 | 2.97464 | 2.44236 | 1 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0.23412 | 0 | 0 | |
Other Current Liabilities, Total | 0.00976 | 0.20599 | 0.283 | ||
Total Liabilities | 24.58 | 9.943 | 5.82591 | 5.78904 | 17.886 |
Total Long Term Debt | 2.289 | 1.712 | 1.82304 | 1.07212 | 0 |
Long Term Debt | 2.289 | 1.712 | 1.82304 | 1.07212 | |
Other Liabilities, Total | 3.831 | 1.231 | 0.38932 | 0.17295 | 15.013 |
Total Equity | 84.052 | 95.818 | 21.5504 | 11.0184 | -0.458 |
Common Stock | 2.217 | 1.995 | 1.84133 | 0.52747 | 0.513 |
Additional Paid-In Capital | 294.874 | 225.537 | 93.0587 | 62.0186 | 215.859 |
Retained Earnings (Accumulated Deficit) | -213.018 | -131.667 | -73.3018 | -51.4798 | -216.83 |
Total Liabilities & Shareholders’ Equity | 108.632 | 105.761 | 27.3764 | 16.8074 | 17.428 |
Total Common Shares Outstanding | 221.6 | 199.381 | 184.012 | 52.6252 | 1.03376 |
Īstermiņa Ieguldījumi | 13.371 | 0 | |||
Redeemable Preferred Stock | 0.001 | 0.001 | 0 | 0 | |
Other Equity, Total | 0.026 | 0 | |||
Other Current Assets, Total | 4.988 | 0 | 7 | 0.172 | |
Property/Plant/Equipment, Total - Gross | 10.584 | 3.125 | 1.29231 | 10.427 | |
Accumulated Depreciation, Total | -0.621 | -0.374 | -0.2257 | -10.286 | |
Treasury Stock - Common | -0.048 | -0.048 | -0.04786 | -0.04786 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Apgrozāmo Līdzekļu Kopsumma | 84.401 | 98.492 | 107.497 | 122.569 | 138.027 |
Nauda un Īstermiņa Ieguldījumi | 76.721 | 90.934 | 101.602 | 115.005 | 129.771 |
Nauda un Ekvivalenti | 68.259 | 77.563 | 101.602 | 115.005 | 129.771 |
Prepaid Expenses | 7.68 | 7.558 | 5.895 | 7.564 | 8.256 |
Other Current Assets, Total | |||||
Total Assets | 96.299 | 108.632 | 116.239 | 130.088 | 141.727 |
Property/Plant/Equipment, Total - Net | 7.952 | 9.963 | 8.557 | 7.325 | 3.345 |
Property/Plant/Equipment, Total - Gross | 8.739 | 10.584 | 9.135 | 7.847 | 3.786 |
Accumulated Depreciation, Total | -0.787 | -0.621 | -0.578 | -0.522 | -0.441 |
Other Long Term Assets, Total | 3.946 | 0.177 | 0.185 | 0.194 | 0.355 |
Total Current Liabilities | 15.683 | 18.46 | 14.907 | 10.338 | 7.687 |
Accounts Payable | 8.092 | 8.062 | 6.46 | 5.921 | 3.896 |
Accrued Expenses | 6.335 | 10.398 | 8.447 | 4.417 | 3.791 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.256 | ||||
Total Liabilities | 20.499 | 24.58 | 20.936 | 15.98 | 10.598 |
Total Long Term Debt | 1.058 | 2.289 | 2.265 | 1.75 | 1.731 |
Long Term Debt | 1.058 | 2.289 | 2.265 | 1.75 | 1.731 |
Other Liabilities, Total | 3.758 | 3.831 | 3.764 | 3.892 | 1.18 |
Total Equity | 75.8 | 84.052 | 95.303 | 114.108 | 131.129 |
Common Stock | 2.265 | 2.217 | 2.168 | 2.163 | 2.158 |
Additional Paid-In Capital | 303.073 | 294.874 | 284.231 | 281.139 | 278.704 |
Retained Earnings (Accumulated Deficit) | -229.516 | -213.018 | -191.079 | -169.157 | -149.686 |
Treasury Stock - Common | -0.048 | -0.048 | -0.048 | -0.048 | -0.048 |
Other Equity, Total | 0.025 | 0.026 | 0.03 | 0.01 | |
Total Liabilities & Shareholders’ Equity | 96.299 | 108.632 | 116.239 | 130.088 | 141.727 |
Total Common Shares Outstanding | 226.427 | 221.6 | 216.688 | 216.15 | 215.631 |
Redeemable Preferred Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
Īstermiņa Ieguldījumi | 8.462 | 13.371 |
- Ikgadējs
- Ceturkšņa
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Neto ienākumi/Sākuma Līnija | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
Nauda no Darbības | -60.079 | -47.941 | -14.7087 | -16.8933 | -15.777 |
Nauda no Darbības | 0.48 | 0.229 | 0.10211 | 0.06061 | 0.45 |
Bezskaidras Naudas Preces | 11.597 | 7.757 | 8.2213 | 6.40129 | -14.779 |
Cash Taxes Paid | 0 | 0.052 | 0.105 | ||
Samaksātie Procenti Naudā | 0.001 | ||||
Izmaiņas Apgrozāmajā Kapitālā | 9.195 | 2.438 | -1.21018 | -3.11255 | 7.195 |
Nauda no Ieguldījumu Darbībām | -16.967 | -1.816 | -0.30683 | -2.35672 | -1.113 |
Kapitālie Izdevumi | -4.457 | -1.066 | -0.30683 | -0.02945 | -2.013 |
Nauda no Darbībām ar Finansēšanu | 59.475 | 120.676 | 31.611 | 25.0665 | 25.351 |
Naudas Plūsma Finansēšanas Posteņos | -0.592 | -8.525 | -1.48355 | -0.17293 | -0.178 |
Akciju Izsniegšana (Atkāpšanās), Neto | 59.567 | 129.211 | 37.822 | 23.7294 | 25.529 |
Neto Izmaiņas Naudā | -17.546 | 70.919 | 16.5955 | 5.81646 | 8.461 |
Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -12.51 | -0.75 | 0 | -2.32727 | 0.9 |
Parādu Izsniegšana (Atkāpšanās), Neto | 0.5 | -0.01 | -4.72744 | 1.51 | |
Ārvalstu Valūtas Ietekme | 0.025 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -16.498 | -81.351 | -59.412 | -37.49 | -18.019 |
Cash From Operating Activities | -18.24 | -60.079 | -43.165 | -28.863 | -15.066 |
Cash From Operating Activities | 0.174 | 0.48 | 0.307 | 0.166 | 0.076 |
Non-Cash Items | 3.053 | 11.597 | 7.721 | 5.75 | 3.497 |
Changes in Working Capital | -4.969 | 9.195 | 8.219 | 2.711 | -0.62 |
Cash From Investing Activities | 3.441 | -16.967 | -1.672 | -1.589 | -0.223 |
Capital Expenditures | -1.612 | -4.457 | -2.433 | -1.589 | -0.223 |
Cash From Financing Activities | 5.496 | 59.475 | 51.3 | 50.338 | 50.102 |
Financing Cash Flow Items | -0.235 | -0.592 | -0.398 | -0.248 | -0.075 |
Issuance (Retirement) of Stock, Net | 5.731 | 59.567 | 51.198 | 50.586 | 50.177 |
Issuance (Retirement) of Debt, Net | 0.5 | 0.5 | 0 | 0 | |
Net Change in Cash | -9.304 | -17.546 | 6.493 | 19.896 | 34.813 |
Other Investing Cash Flow Items, Total | 5.053 | -12.51 | 0.761 | 0 | |
Cash Taxes Paid | 0 | 0 | |||
Foreign Exchange Effects | -0.001 | 0.025 | 0.03 | 0.01 |
Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.359 | 13983184 | 325773 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.9879 | 13014850 | 1186595 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.3269 | 6071506 | -42605 | 2023-04-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7864 | 4661333 | 517806 | 2023-03-31 | LOW |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.1401 | 2974934 | -38269 | 2023-03-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.9278 | 2420929 | 1982473 | 2023-03-31 | MED |
Renaissance Technologies LLC | Hedge Fund | 0.8744 | 2281548 | 858692 | 2023-03-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.6232 | 1626024 | -54370 | 2023-03-31 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.5821 | 1518828 | -101478 | 2023-03-31 | LOW |
Ergoteles Capital | Hedge Fund | 0.5813 | 1516801 | 1516801 | 2023-03-31 | HIGH |
Millennium Management LLC | Hedge Fund | 0.4858 | 1267682 | 1267682 | 2023-03-31 | HIGH |
KVM Holdings, L.L.C. | Corporation | 0.4389 | 1145299 | 0 | 2023-04-13 | |
HRT Financial LP | Investment Advisor | 0.3862 | 1007728 | 1007728 | 2023-03-31 | LOW |
Zhang (Junge) | Individual Investor | 0.3698 | 964904 | 0 | 2023-04-13 | |
BNY Mellon Asset Management | Investment Advisor | 0.3315 | 865067 | 25820 | 2023-03-31 | LOW |
Kompella (Uday B.) | Individual Investor | 0.2702 | 705090 | 0 | 2023-04-13 | |
Nuveen LLC | Pension Fund | 0.2576 | 672249 | -483391 | 2023-03-31 | LOW |
BlackRock Investment Management, LLC | Investment Advisor/Hedge Fund | 0.23 | 600261 | 15607 | 2023-03-31 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 0.1887 | 492420 | -900714 | 2023-03-31 | MED |
BofA Global Research (US) | Research Firm | 0.1878 | 490023 | -2389134 | 2023-03-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group535K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$113M+
Ikmēneša ieguldījumu apjoms
$64M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Par Ocugen, Inc.
Ocugen, Inc. ir biofarmācijas uzņēmums, kas koncentrējas uz gēnu terapijas izstrādi akluma slimību ārstēšanai un COVID-19 vakcīnas izstrādi. Uzņēmuma tehnoloģiju klāstā ietilpst: COVID-19 vakcīnu (0.5), modificējošu gēnu terapijas platformu un jaunas bioloģiskās terapijas tīklenes slimībām. COVID-19 vakcīnas kandidāts ir vērsts uz COVAXIN izstrādi, ražošanu un komercializāciju COVID-19 profilaksei cilvēkiem Ocugen Covaxin teritorijā. COVAXIN ir visa vīrusa inaktivēta COVID-19 vakcīnas kandidāts, un tā sastāvā ir inaktivēts SARS-CoV-2 vīruss. Modifikatora gēnu terapijas platforma ir paredzēta tīklenes slimībām, tostarp pigmentozā retinīta (RP), Lebera iedzimtas amaurozes (LCA) un sausās ar vecumu saistītas makulas deģenerācijas (AMD) ārstēšanai. Uzņēmums izstrādā OCU200, bioloģisko preparātu, kas paredzēts diabētiskās makulas tūskas (DME), diabētiskās retinopātijas (DR) un mitrās AMD ārstēšanai. OCU400, tās pirmais kandidātprodukts, kas tiek izstrādāts, izmantojot tās modificējošo gēnu terapijas platformu.
Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 535 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com